Trial Profile
A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
- Indications Advanced breast cancer; Cancer; Colorectal cancer; Early breast cancer; Gastrointestinal cancer; Gynaecological cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
- Focus Adverse reactions
- 17 Jan 2020 Status changed to completed.
- 07 Jun 2011 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.
- 19 Feb 2010 New trial record